

Shortage Prevention Plan Medicinal Oxygen

Introduction:

This document covers the medicinal product Oxygen, with an assay of more than 99,5% (V/V) and produced via the cryogenic distillation of ambient air. The product has a Ph.Eur. monograph, 0417, for many years and is one of the most commonly used medicinal products worldwide. Usually, medicinal oxygen is supplied to healthcare facilities as a licensed medicinal product in defined packages, most commonly in large volumes as a liquid product stored at the healthcare facility site in insulated storage tanks and distributed via the medical gas pipeline supply system owned and operated by the healthcare facility. Smaller healthcare facilities, care homes and individual patients at home are generally supplied with gaseous oxygen compressed in cylinders or as a liquid in small cryogenic vessels.

EIGA emphasizes that in Europe, and as confirmed to the European Medicines Agency (EMA), during the COVID-19 pandemic our members confirmed that at no time was there a shortage of oxygen to patients in healthcare facilities or for home oxygen use. Due to the significant increase in demand for oxygen during the COVID-19 pandemic, some issues were encountered in relation to equipment and manpower, but these were resolved via regulatory flexibilities agreed to by national authorities.

Lessons have been learned from the COVID-19 pandemic, with respect to the design and operation of gas supply systems and pipeline distribution systems, and as such the industry has renewed its commitment to review and improve relevant standards associated to medical oxygen production and distribution methods, via increased active participation in regional and national standardization bodies, such as ISO and ANSI, in order to ensure that the lessons learnt from the COVID-19 pandemic are incorporated into the relevant standards.

EIGA has used Technical Report No. 68, "Risk-Based Approach for Prevention and Management of Drug Shortages", as prepared by the Parenteral Drug Association (PDA) in 2014 as part of the inter-association collaborative contribution to the EMA (European Medicines Agency) Initiative on medicinal product shortages caused by manufacturing and GMP compliance issues. The document can be freely downloaded from the PDA website.

The risk triage method is a simple four-step process that uses a preliminary hazards analysis approach to evaluate the risk of a drug shortage by considering the therapeutic use of a product, availability of alternatives, and likelihood of occurrence. The process assigns a risk priority level based on a combination of the potential impact to the patient and likelihood of a drug shortage, and then recommends risk controls for the assessed product. The method uses discrete information and key words to assign a priority level for each element, making the assessment focus on product information and avoiding discussions on general subjective terms.

The steps in the triage process are as follows:

1. Identify risk level (impact to patient) based on therapeutic use and availability of alternatives.

© EIGA grants permission to reproduce this publication provided the Association is acknowledged as the source

2. Determine the likelihood of a drug shortage for the product.
3. Determine the risk priority level based on a combination of impact to patient and likelihood of a drug shortage for the product.
4. Plan and implement the suggested risk controls for the assessed product based on the risk priority level.

Step 1:

			Availability of Alternatives		
			No Alternatives Available	Alternative Products Available: Similar Therapy	Exact Product Available but in Other Presentations
Therapeutic Use & Consequences if Product is not Available	Medically necessary product, life supporting or life sustaining	Fatal or severe irreversible harm if the patient is not treated with the product	Risk Level A	Risk Level A	Risk Level B
	Acute short term or chronic long term	Severe harm but reversible if patient is not treated with the product	Risk Level A	Risk Level B	Risk Level C
	Other indications	inconvenience if patient is not treated with the product	Risk Level B	Risk Level C	Risk Level C

Typical Indications of medicinal Oxygen:

Normobaric oxygen therapy (Oxygen therapy at normal pressure):

- Treatment or prevention of hypoxia and hypoxaemic conditions.
- Treatment of cluster headache.

Hyperbaric oxygen therapy (Oxygen therapy at high pressure)

- Treatment of serious carbon monoxide poisoning irrespective of the COHb content in the blood (in particular essential in patients who after exposition to carbon monoxide have lost consciousness, have neurological symptoms, cardiovascular failure or serious acidosis or pregnant patients).
- Treatment of decompression sickness, or of air/gas embolism of a different origin.
- As supporting treatment in cases of osteoradionecrosis.
- As supporting treatment in cases of clostridial myonecrosis (gas gangrene).

Therefore, the assessment is that Oxygen is a medically necessary product and is life supporting and life sustaining.

In the assessment of alternatives, the outcome is that there are many “Exact products available” as there are many Marketing Authorisation Holders (MAHs) within each EU member state having authorisations for medicinal oxygen. It should also be noted that these products are present in the exact same presentation, therefore lowering the risk even further.

With the assessment of “Therapeutic Use & Consequences if Product is not Available” as “Medically necessary product, life supporting or life sustaining” and “Availability of Alternatives” as “Exact Product Available” – it is classed as **RISK LEVEL B**.

© EIGA grants permission to reproduce this publication provided the Association is acknowledged as the source

EUROPEAN INDUSTRIAL GASES ASSOCIATION AISBL
AVENUE DE L'ASTRONOMIE 30 • B-1210 BRUSSELS
PHONE +32 2 217 70 98 • E-mail : info@eiga.eu www.eiga.eu

AVA Documents
Document Sharing Hub

Step 2:

For the likelihood analysis, the following main sources of hazards were assessed:



according to the following criteria:

LOW: Robust controls exist for a hazard

MODERATE: Limited controls exist for a hazard

HIGH: No controls exist for a hazard

Drug Substance:

For oxygen, the drug substance is considered to be oxygen manufactured at Air Separation Units (ASUs) via the cryogenic distillation of ambient air. There are many ASUs within each member state that can produce significantly more oxygen than is required for patient use across Europe, with only a small percentage of oxygen produced at an ASU being used for healthcare purposes. Manufacturing of oxygen is performed directly in the EU, with associated short delivery times and via a very stable production process in accordance with GMP requirements. Manufacture of the drug substance is performed either directly on the site of the manufacture of the finished product or is transported to the finished product manufacturing site via road tanker by road. The location of the drug substance manufacturer, when different to the finished product manufacturing site, is usually within a few hours from the finished product manufacturing site.

- ✓ Back up available
- ✓ Production already located within European Union
- ✓ No possibility of shortage of starting material (ambient air)
- ✓ Short transport routes if not onsite
- ✓ Well established and highly reliable process producing high quality products, no deliveries with OOS over the last period (10 years) of deliveries at least
- ✓ High minimum stocks of drug substance at the manufacturing site

➔ **The resulting risk of failure of Drug Substance supply is considered:**

LOW

© EIGA grants permission to reproduce this publication provided the Association is acknowledged as the source